JMP Securities Reiterates “Market Outperform” Rating for OptimizeRx (NASDAQ:OPRX)

JMP Securities reiterated their market outperform rating on shares of OptimizeRx (NASDAQ:OPRX) in a report released on Friday, Benzinga reports. JMP Securities currently has a $16.00 price objective on the stock.

Other equities research analysts have also issued research reports about the company. Royal Bank of Canada restated an outperform rating and set a $17.00 price objective on shares of OptimizeRx in a research report on Monday, April 1st. Stifel Nicolaus restated a buy rating and set a $13.00 price target on shares of OptimizeRx in a report on Wednesday, May 15th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of Moderate Buy and a consensus price target of $16.00.

OptimizeRx Stock Down 1.5 %

OPRX stock opened at $10.57 on Friday. The firm has a 50-day moving average price of $11.06 and a 200-day moving average price of $12.74. OptimizeRx has a 12 month low of $6.92 and a 12 month high of $16.65. The company has a current ratio of 2.88, a quick ratio of 2.88 and a debt-to-equity ratio of 0.26. The stock has a market capitalization of $193.11 million, a P/E ratio of -10.36 and a beta of 1.28.

OptimizeRx (NASDAQ:OPRX) last released its quarterly earnings data on Tuesday, May 14th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.16). The company had revenue of $19.69 million for the quarter, compared to analyst estimates of $18.66 million. OptimizeRx had a negative return on equity of 6.96% and a negative net margin of 23.10%. During the same quarter in the prior year, the company earned ($0.34) earnings per share. As a group, equities research analysts anticipate that OptimizeRx will post -0.42 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Kennedy Capital Management LLC acquired a new stake in shares of OptimizeRx in the third quarter valued at about $4,323,000. AWM Investment Company Inc. increased its position in OptimizeRx by 75.8% during the 3rd quarter. AWM Investment Company Inc. now owns 782,571 shares of the company’s stock valued at $6,088,000 after purchasing an additional 337,303 shares during the period. Millrace Asset Group Inc. bought a new position in OptimizeRx during the 4th quarter worth approximately $1,917,000. G2 Investment Partners Management LLC lifted its position in shares of OptimizeRx by 26.0% in the 4th quarter. G2 Investment Partners Management LLC now owns 468,120 shares of the company’s stock worth $6,699,000 after purchasing an additional 96,646 shares during the period. Finally, Essex Investment Management Co. LLC bought a new stake in shares of OptimizeRx in the 1st quarter valued at $1,053,000. 76.47% of the stock is owned by institutional investors.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.